5
项与 Allogenic gamma delta T cell therapy (Beijing GD Initiative Cell Therapy Technology) 相关的临床试验 / Not yet recruiting早期临床1期IIT The Safety and Efficacy Assessment of Allogeneic γδ T Cells Combined With Targeted Therapy and Immunotherapy in Hepatocellular Carcinoma Patients
The purpose of this study is to evaluate the safety and efficacy of allogeneic γδ T cells combined with targeted therapy and PD-1 monoclonal antibody in patients with hepatocellular carcinoma resistant to PD-1 monoclonal antibody.
Hepatocellular Carcinoma
/ Not yet recruiting临床1期IIT The Safety and Efficacy Assessment of Allogeneic γδ T Cells Combined With Targeted Therapy and Immunotherapy in Hepatocellular Carcinoma Patients
The purpose of this study is to evaluate the safety and efficacy of allogeneic γδ T cells combined with targeted therapy and PD-1 monoclonal antibody in first-line treatment of patients with hepatocellular carcinoma.
/ Not yet recruiting早期临床1期IIT Efficacy and Safety of Allogeneic γδ T Cells (γδ T Cells) Combined With Interferon-alpha1b (IFN-α1b) or PD-1 Monoclonal Antibody in Neoadjuvant Treatment of Stage III-IV Resectable Melanoma
The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells combined with recombinant human interferon-α1b (IFN-α1b) or PD-1 monoclonal antibody in neoadjuvant treatment of patients with Stage III-IV resectable melanoma.
100 项与 Allogenic gamma delta T cell therapy (Beijing GD Initiative Cell Therapy Technology) 相关的临床结果
100 项与 Allogenic gamma delta T cell therapy (Beijing GD Initiative Cell Therapy Technology) 相关的转化医学
100 项与 Allogenic gamma delta T cell therapy (Beijing GD Initiative Cell Therapy Technology) 相关的专利（医药）
100 项与 Allogenic gamma delta T cell therapy (Beijing GD Initiative Cell Therapy Technology) 相关的药物交易
